Funda Meric-Bernstam
UT MD Anderson · University of Texas MD Anderson Cancer Center LAO · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
15
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
4 more share only the name and are not shown
Trial papers in breast cancer
42
PubMed author-name match
Trials
Studies that name Funda Meric-Bernstam as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:57 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07756515 · Chatbot Implementation In The Clinical Informed Consent ProcessM.D. Anderson Cancer Center · recruiting · Informed Consent · principal investigator
- Ph1NCT06364410 · Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsNational Cancer Institute (NCI) · recruiting · Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 · principal investigator
- Ph2NCT06311214 · Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)National Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1/Ph2NCT05797168 · Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsAstraZeneca · recruiting · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer · principal investigator
- Ph2NCT04957615 · Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 ExpressionM.D. Anderson Cancer Center · active not recruiting · Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm · principal investigator
- Ph2NCT03872427 · Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN StudyNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor · principal investigator
- N/ANCT02508662 · Registry Study for Personalized Cancer TherapyM.D. Anderson Cancer Center · completed · Advanced Cancers, Solid Tumors · principal investigator
- N/ANCT02437617 · Genomic Profiling Assay in Phase IM.D. Anderson Cancer Center · completed · Advanced Cancers · study chair
- N/ANCT01772771 · Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy ProgramM.D. Anderson Cancer Center · recruiting · Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm · principal investigator
- Ph2NCT01277757 · Akt Inhibitor MK2206 in Treating Patients With Advanced Breast CancerNational Cancer Institute (NCI) · completed · Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer · principal investigator
- Ph1NCT01263145 · MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerNational Cancer Institute (NCI) · completed · Adult Solid Neoplasm, Recurrent Breast Carcinoma, Stage IV Breast Cancer · principal investigator
- Ph1NCT01095913 · Fluorescent Dyes for Lymph Node MappingM.D. Anderson Cancer Center · completed · Breast Cancer · study chair
- Ph2NCT00877500 · Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyM.D. Anderson Cancer Center · active not recruiting · Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma · principal investigator
- Ph1NCT00645541 · Axillary Reverse Mapping for Invasive Carcinoma of the BreastM.D. Anderson Cancer Center · completed · Breast Cancer · principal investigator
- Ph1NCT00543504 · Bevacizumab in Multiple Phase I CombinationsM.D. Anderson Cancer Center · completed · Advanced Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Center for Clinical and Translational SciencesUM1TR004906 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2024 to 2026 · $5,479,769 awarded in 2026Same name and institution; not confirmed by an ID
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $170,449 awarded in 2026Grant number is on one of their registry trials
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2014 to 2026 · $1,519,430 awarded in 2026Grant number is on one of their registry trials
- Training of Academic Surgical OncologistsT32CA009599 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2010 to 2023 · $625,531 awarded in 2023Same name and institution; not confirmed by an ID
- University of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2022 · $557,633 awarded in 2022Same name and institution; not confirmed by an ID
- Informatics to enable routine personalized cancer therapyU01CA180964 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · fiscal years 2013 to 2015 · $316,190 awarded in 2015Same name and institution; not confirmed by an ID
- Akt Inhibitor MK-2206 for Breast Cancers with a PIK3CA Mutation and/or PTEN lossR21CA159270 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2011 to 2012 · $262,015 awarded in 2012Same name and institution; not confirmed by an ID
- Targeting mTOR for Cancer TherapyR01CA112199 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2005 to 2009 · $233,253 awarded in 2009Same name and institution; not confirmed by an ID
- Role of Nuclear Tyrosine Rak in Breast CancerK08CA091834 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2001 to 2006 · $68,040 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013Named on NCT01277757, NCT01263145
- Phase I Studies of Targeted Anti-Cancer TherapiesU01CA062461 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI James C Yao · fiscal years 1994 to 2013Named on NCT01263145
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 09:57 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.J Clin Oncol · 2024980 citationsRCR 138.3
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med · 2021778 citationsRCR 43.5
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.Cancer Discov · 2022231 citationsRCR 15.5
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.Breast Cancer Res · 2019186 citationsRCR 6.9
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.J Clin Oncol · 2024176 citationsRCR 21.9
- 168 citationsRCR 5.4
- 140 citationsRCR 3.7
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.Breast · 2016112 citationsRCR 3.1
- Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Cancer Discov · 202099 citationsRCR 3.3
- 93 citationsRCR 2.4